Literature DB >> 11202193

[Cyclophosphamide-induced apoptosis of murine lymphosarcoma cells in vivo].

V I Kaledin1, V P Nikolin, T A Ageeva, O A Timofeeva, M L Filipenko, G M Ronichevskaia, T S Morozkova, N A Popova, T Iu Baĭmak.   

Abstract

The antitumor action of combination chemotherapy (cyclophosphamide + adriamycin + vincristin + prednisolone) for transplantable nitrosomethylurea-induced lymphosarcoma was studied in male CBA mice. Single injections of the mixture were followed by complete regression of tumors of up to 2 cm in diameter. The effect was shown to be caused by cyclophosphamide (CP) alone, by inducing apoptosis. The other components failed to potentiate the CD effect. Being useless, they are likely to cause harm by contributing to the overall toxic effect of therapy. The nature and duration of CP-induced remission appeared dose-dependent: on day 50 of the administration of 50, 100 and 150 mg/kg body, tumors were detected in 100, 55 and 0% of the animals, respectively. Such means of apoptosis induction as glycocorticoid treatment and ionizing radiation did not cause complete regression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11202193

Source DB:  PubMed          Journal:  Vopr Onkol        ISSN: 0507-3758


  3 in total

1.  High apoptosis-inducing and antitumor activities of the products of biological but not chemical cyclophosphamide activation.

Authors:  V I Kaledin; V P Nikolin; M R Galyamova; E D Vasil'eva; T Yu Baimak; N A Popova
Journal:  Dokl Biol Sci       Date:  2002 Sep-Oct

2.  Murine models of B-cell lymphomas: promising tools for designing cancer therapies.

Authors:  Sabrina Donnou; Claire Galand; Valérie Touitou; Catherine Sautès-Fridman; Zsuzsanna Fabry; Sylvain Fisson
Journal:  Adv Hematol       Date:  2012-02-12

3.  Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.

Authors:  Elena P Goncharova; Julia S Ruzhenkova; Ivan S Petrov; Sergey N Shchelkunov; Marina A Zenkova
Journal:  J Transl Med       Date:  2016-08-18       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.